Førstesiden | Mest lest | Kategorier | Ord i nyhetene | 1928 kilder | Hos deg? | Om Mylder
Anbefalte saker | Skjul ingresser | Skjul tekstlenker | Sett som startside | Mobil | RSS | MONITOR | Søk
Stem!
Bør andre også lese denne saken? Klikk på "Stem"-knappen, og artikkelen hopper et lite hakk oppover på Mest lest-listen.

New cystic fibrosis drug highlights approval dilemma

With drugs for rare diseases, regulators need to balance the consequences of side effects against the demands of patients with no other options
(New Scientist 07.02.2012 kl. 16:37) Les saken >>




Saken inneholder følgende stikkord (sortert alfabetisk): $75 15:37 07 22 90 1000 2012 2851 Act Administration Aldhous Although Aurora Before But California Cambridge Colorado Crnic Cystic DNA Diseases Down Drug Drugs Ed Emil EveryLife FDA Fast February Fibrosis Food Foundation Great House III If In Instead Institute It Kakkis Kalydeco Linda Magazine Massachusetts McCabe Methods New Peter Rare Representatives Sandy Scientist Subscribe Such Syndrome The US Ultra Unlimited Vertex Walsh We're With ability able about accept accept accepted access after against agency all allowed also an and animal anything apply approach approval approved approving are as at available backing balance be been being benefit better biological bolder by called can carry cause causes cent change cheap clog confirm consequences considered content could coupled course cystic defect delivered demands develop dilemma discovered discovery disease disease diseases diseases disorder disorders? don't drug drugs effective effectiveness effects encourage every evidence exhalation exist far fast feasible few fibrosis find flexibility for from gene genetic geneticists' get: given go go had happen happy has have heads here's highlights how hundred if improvement in indicator instance intractable is issue it judgement just landmark let life limited lived long longer lungs magazine manner many market may meant measure million molecules moment: more mucus mutation mutations need no normal normally not now! numbers obstacles of online only options options other others patients pave people per pharmaceuticals phase point price promising quality rare rather reached receive recent regulators regulatory results risks route rub: run safe safety save savings say says scientific screening sequencing show side so some specific speeded spokeswoman sticky strength strong studies subscribers surrogate systems take tends test tested than that the their there they thousands three to together transformed treat trials two up waiting was wasn't way we week were where which who will with would wrong years you'll –

Annonser: • Videoforklaring.no - Si det med video! • DinSMS.no - Send gratis SMS • Gavetips fra Gaveguide

Copyright © Mylder AS 2000-12. Ansv. utgiver Tom W. Ottmar
Nyhetsovervåking
Nyhetsovervåking
Støtt Amnesty!
Børs
Oslo: 395,27 +0,79%
Dow: 12580,69 +1,01%
Nasdaq: 2870,99 +1,18%
FTSE: 5391,14 +0,65%
DAX: 6396,84 1,16%
CAC 40: 3084,70 +1,37%
Nikkei: 8657,08 +0,74%
Hang S.: 19 055 +1,35%
Oppdatert: 29.05.12 kl. 22:10
Mest lest siste 16t:
1. Moss AUF aksjonerte på Rådhusbrua
2. Breivik nektet å la seg teste for spillegalskap
3. Grunneierne krever sjøkabel
4. Bieber-fansen i ekstase: - Tenk at vi puster samme luft ..
5. Bieber-feber i Oslo - tusenvis venter på superstjernen
6. 115 nye i streik i fylkeskommunen
7. Bassengene på Alvim fylles
8. Må regne med større kø på Rygge
9. Arrangerer likevel Momarkedet
Anbefalt siste 4 døgn: NY!
  1. Fuktig løpsfest
  2. Vurderer å bygge undersjøisk tunnel til La Manga
TV i dag
• Se.no
• VG
Dagens sjekk
Radiolyd
Valuta
• EUR 7,52 • USD 6,01
• SEK 83,69 • DKK 101,21
• GBP 9,41 • JPY 7,55
Oppdatert: 29.05.12 kl. 22:12
Været
Tips en venn om MYLDER!
Din e-postadresse:
 		 Adressen til den vil du tipse:

  
Se teksten som blir sendt (åpnes i nytt vindu)